comparemela.com

Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Iceland ,Japan ,Liechtenstein ,Norway ,Stefan Klotter ,Deric Dube ,Drug Administration ,European Union ,Travere Therapeutics Inc ,Exchange Commission ,Nasdaq ,Committee For Medicinal Products Human Use ,European Commission ,European Medicines Agency ,New Drug Application ,Medicinal Products ,Human Use ,About Travere ,Travere Therapeutics ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Lassen Sie ,

comparemela.com © 2020. All Rights Reserved.